AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00586300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training and self-management training programs
Description: This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2.
Study NCT00618397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
Study NCT02854566 — intervention group
Intervention type: DEVICE
Intervention: osteosynthesis
Description: Fracture reduction and fixation with screws/plates/cables (standard of care)
Study NCT03657199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac computed tomography
Description: Routine computed tomography of the heart before discharge
Study NCT03551678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active feedback gait retraining
Description: The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2a
Study NCT02175966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon α-2a
Study NCT01696864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand tutor rehabilitation device
Description: A rehabilitation device for the hand
Study NCT01696864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm tutor rehabilitation device
Description: A rehabilitation device for the arm
Study NCT03111979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Study NCT03111979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04053478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine in solution, at applicable concentrations based on literature
Study NCT04053478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine, at applicable concentrations based on literature
Study NCT04053478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine, at applicable concentrations based on literature
Study NCT04053478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin, at applicable concentrations based on literature
Study NCT00583869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Study NCT00583869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Study NCT00583869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Study NCT02189616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: send weekly mobile phone short message reminders to the intervention group
Study NCT02189616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS consultation
Description: told patients to consult qualified asthma nurses by SMS when they need
Study NCT02189616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: patients are asked to fill in their paper asthma diary daily for 3 months
Study NCT02189616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: patients are asked to fill in their paper asthma diary daily for 3 months
Study NCT00878345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine sedation protocol
Description: Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
Study NCT00878345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentobarbital sedation protocol
Description: Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation.
Study NCT03387410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous IRDye 800BK
Description: Fluorescence of the ureter using IRDye 800BK
Study NCT02042690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haplo-identical HSCT
Description: Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
Study NCT02042690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
Study NCT02218359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
Study NCT02218359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized placebo
Description: Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
Study NCT02218359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: Open-label crossover for all patients Days 6-10
Study NCT02218359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation Solution
Description: Open-label crossover for all patients Days 6-10
Study NCT01708928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT02457728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBandFix8
Description: Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
Study NCT01247688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
Study NCT01247688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
Study NCT01247688 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 1.75Gy/fraction will be given on day -9, -8, -7, -6
Study NCT01247688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Stem Cell Infusion
Description: The cord blood stem cells will be infused on day 0
Study NCT03700710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Approach
Description: For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.
Study NCT03700710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian-led Approach
Description: For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis.
Study NCT03120585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Management Intervention
Description: Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR >4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
Study NCT04147728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
Study NCT04147728 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
Study NCT00613847 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
Description: Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
Study NCT00613847 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
Description: Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
Study NCT02189876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
Study NCT02189876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
Study NCT02189876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FemAALES
Description: Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
Study NCT04368052 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein
Description: Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
Study NCT01567774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: os, 10 mg, once per day, for 30 days
Study NCT03147690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
Study NCT02029066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 gel
Description: 2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.
Study NCT01664663 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiochemotherapy to 68 Gy
Study NCT01664663 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalated radiochemotherapy up to 84 Gy
Study NCT04275011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance and Impact Exercise
Description: Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (\~80% 1RM) or 6 (\~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
Study NCT04275011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Balance and Postural Exercise
Description: Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
Study NCT01076673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells and hyaluronic acid injections
Description: Peripheral blood stem cells and hyaluronic acid injections
Study NCT01076673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid injections
Study NCT01703572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-52M51
Study NCT04194463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChemoFit exercise prehabilitation intervention
Description: Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
Study NCT00618592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOp carbohydrate drink
Description: 800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
Study NCT01757535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: 300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
Study NCT01757535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Study NCT01508611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30% silver diammine fluoride
Description: The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children.
Study NCT01508611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene
Description: With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique